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Introduction
For years many physicians firmly believed that a hemoglobin
of 10 g/dl and a hematocrit of 30% represented desirable
goals in anemic patients, especially those undergoing surgi-
cal procedures and those with cardiac disease. Despite the
paucity of objective data to support this contention, the so-
called ‘10/30 rule’ persisted until recently [1]. Most authori-
ties attribute this bias to a 1942 report by Adams and Lundy
[2] in which they recommended a hemoglobin of 10 g/dl and
a hematocrit of 30% in the perioperative setting based on
their clinical experience. Recent studies [3–7] have provided
compelling evidence against the 10/30 rule in critically ill
patients as well as in the perioperative period. Despite these
data, many clinicians continue to provide transfusion using a
hematocrit of 30% as a ‘transfusion trigger’ [8]. However,
current practice and available evidence is gradually shifting
from transfusing to an arbitrary hemoglobin (10/30) to achiev-
ing a level of hemoglobin necessary to meet the patient’s
tissue oxygen demands [9,10].
The optimal hemoglobin level is more closely approximated
by physiologic measurements [11]. In patients who are not
critically ill, most studies have demonstrated that a substan-
tially lower hemoglobin level (7 g/dl) can be tolerated if
normovolemia is maintained. Experience in Jehovah’s Witness
patients has allowed an assessment of human tolerance of
severe acute anemia and demonstrated the feasibility of sur-
vival in the case of very low hematocrit [12–18]. In a review of
61 medical and surgical reports published from 1970 to
1993, Viele and Weiskopf [17] identified 50 deaths attrib-
uted to anemia in untransfused Jehovah’s Witnesses with
hemoglobin concentrations of 8 g/dl or less, or hematocrit of
24% or less. Of the 50 deaths, 23 were thought to be primar-
ily due to anemia. Except for three patients who died after
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Abstract
Despite the increasing availability of data supporting more restrictive transfusion practices, the risks
and benefits of transfusing critically ill patients continue to evoke controversy. Past retrospective and
observational studies suggested that liberal transfusion strategies were more beneficial in patients
whose hematocrit levels fell below 30%. An expanding body of literature suggests that an arbitrary
trigger for transfusion (the ‘10/30 rule’) is ill advised. A recent randomized controlled trial provided
compelling evidence that similar, and in some cases better, outcomes result if a restrictive transfusion
strategy is maintained. The impact of this accumulating evidence on clinical practice is evident in large
reports, which show that the average transfusion trigger in critically ill patients was a hemoglobin level
in the range 8–8.5 g/dl. Based on the available evidence, transfusion in the critically ill patient without
active ischemic heart disease should generally be withheld until the hemoglobin level falls to 7 g/dl.
Transfusions should be administered as clinically indicated for patients with acute, ongoing blood loss
and those who have objective signs and symptoms of anemia despite maintenance of euvolemia. The
hemoglobin level at which serious morbidity or mortality occurs in critically ill patients with active
ischemic heart disease is a subject of continued debate but it is likely that a set transfusion trigger will
not provide an optimal risk–benefit profile in this population.
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cardiac surgery, all patients whose deaths were attributed to
anemia died with hemoglobin concentrations of 5 g/dl or less.
There were 25 survivors with a hemoglobin of 5 g/dl or less.
Recently, Weiskopf and coworkers [19] conducted an inter-
ventional study to determine whether acute, severe iso-
volemic reduction in hemoglobin levels to 5 g/dl in healthy,
resting individuals would result in inadequate cardiac com-
pensatory mechanisms, and therefore compromise oxygen
delivery. No evidence of inadequate oxygenation, as
assessed by lack of change in oxygen consumption and
plasma lactate concentration, was noted in the 11 preopera-
tive patients and 21 nonsurgical volunteers with hemoglobin
levels as low as 5 g/dl.
Anemia in the critically ill patient
Anemia in the setting of critical illness is quite prevalent, with
37–44% of patients receiving at least one blood transfusion
during their intensive care unit (ICU) stay [20,21]. In one
representative study [8], 85% of patients with an ICU length
of stay greater than 1 week received at least one blood trans-
fusion. In more than two thirds of these cases blood transfu-
sion was not associated with acute blood loss. Concerns
over the deleterious effects of anemia are increasingly being
balanced by an increased awareness of the serious, well doc-
umented consequences of packed red blood cell (RBC)
transfusion [22].
In a pivotal study published in 1999, Hebert and coworkers
[3] prospectively randomized 838 critically ill ICU patients
with hemoglobin under 9 g/dl to one of two transfusion
strategies. The control group (‘liberal strategy’) received
transfusion of packed RBCs when the hemoglobin fell below
10 g/dl. The study group (‘restrictive strategy’) received trans-
fusion of packed RBCs when hemoglobin fell below 7 g/dl.
The in-hospital mortality rate was significantly lower in the
restrictive strategy group. The 30-day mortality rate was not
significantly different between groups but was significantly
lower with the restrictive strategy in patients who were less ill
(Acute Physiology and Chronic Health Evaluation II score
≤20) and those who were younger (age <55 years). There
was no difference in mortality between groups in patients
with clinically significant heart disease. A restrictive strategy
of RBC transfusion is at least as effective and possibly supe-
rior to a liberal transfusion strategy in critically ill patients, with
the possible exception of patients with acute myocardial
infarction and unstable angina.
Current evidence suggests that clinicians are reconsidering
more conservative transfusion practices in light of these and
similar data. Vincent and coworkers [20] conducted a cross-
sectional study intended to evaluate transfusion practices in
146 European ICUs. They reported that pretransfusion hemo-
globin concentrations (8.4 g/dl) are currently lower than
those previously cited [20,23]. Data from a prospective, multi-
center, observational trial [21] suggest a similar trend toward
more restrictive transfusion practices in the USA. The mean
pretransfusion hemoglobin was 8.6 ± 1.7 g/dl [21]. This shift
toward restrictive transfusion policies may in part be related
to the work published by the Canadian Critical Care Trials
Group.
Anemia in the patient with cardiovascular
disease
The hemoglobin concentration at which risk for death or
serious morbidity occurs was investigated by Carson and col-
leagues [24] using a retrospective cohort of 1958 patients
who underwent surgery and declined blood transfusion. The
primary outcome variable was 30-day mortality. Cardiovascu-
lar disease was defined as a history of angina, myocardial
infarction, congestive heart failure, or peripheral vascular
disease. In patients with preoperative hemoglobin levels of
12 g/dl or greater the mortality rate was 1.3%, whereas
patients with preoperative hemoglobin levels of less than
6 g/dl had a mortality rate of 33.3%. The authors concluded
that low preoperative hemoglobin substantially increases the
risk for death and serious morbidity [24].
The threshold for transfusion in the critically ill or periopera-
tive patient with known coronary artery disease is still
debated. The traditional belief is that anemic patients with
coronary artery disease are at high risk for myocardial
ischemia or infarction because they cannot increase oxygen
extraction or augment coronary arterial flow. Retrospective
studies to date in this population, including the study by
Carson and colleagues [24], suggest that critically ill patients
with cardiac disease had higher mortality when hemoglobin
levels dropped from approximately 10 g/dl perioperatively to
6.0–6.9 g/dl. In fact, the adjusted odds of death in patients
with cardiovascular disease increased five-fold (from 2.3 to
12.3).
There is little available evidence supporting the use of blood
transfusions in the setting of acute myocardial infarction,
excluding retrospective work based on a large administrative
discharge database done by Wu and colleagues [25]. Ignor-
ing the significant limitations of the study design and
methods, Wu and coworkers reported that patients with
lower hematocrit values on admission had higher 30-day mor-
tality rates. At least one randomized controlled trial has sug-
gested that lowering the hemoglobin threshold for transfusion
in aortocoronary bypass grafting procedures to 8 g/dl post-
operatively does not adversely affect outcome [26]. There is
some suggestion that cardiac bypass patients with higher
hematocrit levels postoperatively are more likely to sustain a
postoperative myocardial infarction [6]. In this setting, both
study groups consisted of patients whose surgical lesions
were corrected, and as such, they may have behaved differ-
ently from patients with fixed cardiac disease. There is sub-
stantial evidence on the beneficial effect of β-blockade in
patients who have or are at risk for coronary artery disease in
reducing mortality as well as the incidence of cardiovascularS13
complications [27]. However, of the recent studies investigat-
ing anemia in cardiac disease, all have failed to control for
confounding variables such as β-blockade and heart rate.
The investigators in the Transfusion Requirements in Critical
Care (TRICC) trial [28] performed a subgroup analysis of the
main study to include patients who were thought to be at
increased risk for complications associated with anemia
because of a diagnosis related to coronary artery disease.
Those investigators analyzed 357 patients and found no sig-
nificant difference in 30-day mortality between the restrictive
and the liberal transfusion strategies. Other outcome mea-
surements including multiorgan dysfunction scores, ICU and
in-hospital length of stay were superior in the restrictive
strategy group. Furthermore, there was a greater incidence
of pulmonary edema, a common complication of blood trans-
fusion, in the liberal transfusion strategy group (10.7%
versus 5.3%) than in the restrictive group [3]. Intuitively,
transfusion in the asymptomatic patient with ischemic heart
disease and left ventricular dysfunction may actually be detri-
mental by precipitating pulmonary edema. In a subgroup with
severe ischemic heart disease (n = 257), the absolute sur-
vival rate was lower in the restrictive strategy group than in
the liberal strategy group, but this difference was not statisti-
cally significant. The authors concluded that a restrictive
transfusion strategy appeared to be safe in most critically ill
patients with cardiovascular disease, with the possible
exception of patients with acute myocardial infarction and
unstable angina. Because this conclusion was derived from
a subgroup analysis, caution is warranted in the interpreta-
tion of these results.
The critically ill patient with active ischemic cardiac disease
continues to represent a ‘gray area’ in the literature. Under
these circumstances, it is prudent to recommend individualiz-
ing transfusion decisions to meet the patient’s specific
myocardial oxygen supply/demand, which may change during
the course of their illness [29]. Arbitrary application of the
10/30 rule may result in avoidable adverse outcomes and as
such can no longer be advocated as a transfusion trigger in
any patient population.
Conclusion
Anemia in the setting of critical illness is prevalent. Based on
the available data, it appears appropriate and safe to withhold
transfusion based on the hemoglobin or hematocrit level until
the patient’s hemoglobin is 7 g/dl or less. Regarding patients
with cardiac disease but without acute myocardial infarction
or unstable angina, evidence from the TRICC study suggests
that this approach is safe in this group as well, provided
euvolemia is maintained. There is still controversy about this
group of patients, however, and more trials addressing trans-
fusion triggers in patients with coronary artery disease are
needed. Given the well documented risks associated with
blood transfusion [22], these data strengthen the contention
that blood transfusion should be carefully considered and
that the decision to transfuse RBCs cannot be justified by the
10/30 rule.
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